Total: $971.91M

Company
(Symbol)#
(M)

Type Of
Financing

Number Of
Shares, Units
Or Warrants

Amount
Raised
(M)

Investors; Placement Agents; Details
(Date)@


Arius
Research Inc.
(Canada; TSE:ARI)

Private placement of stock and warrants

3.4S and 3.4W

C$2.55 (US$2)

Biotechnology Value Fund LP and associated funds bought the shares at C$0.75 each; the two-year warrants are exercisable at the same price (9/28)

Australian
Cancer
Technology
Ltd.
(Australia;
ASX:ACU)

Private placement of stock and warrants

9.485S and 1.654W

A$3.79 (US$2.63)

About 60% of the shares were placed with Mercury Investments Ltd., and the remainder were underwritten by Jaguar Advisory Services Pty. Ltd.; they sold at A$0.40 each; the three-year options are exercisable at A$0.60 per share; Hunting Party Securities Ltd. also was a placement agent (9/1)

Biopure
Corp.
(BPUR)

Private placement of stock and warrants

21.37S and 10.69W

$8.33

Biopure sold the Class A shares covered by a shelf registration statement to institutional and individual investors at $0.39 each; the warrants are exercisable at $0.42 per share; C.E. Unterberg, Towbin LLC was placement agent (9/14)

Bioxel
Pharma Inc.
(Canada; TSE:BIP)

Private placement of stock and warrants

8.04U

C$3.3 (US$2.53)

The units, sold at C$0.41 each, consist of one share and a two-year warrant for the purchase of one share at C$0.51; Canaccord Capital Corp. led the deal, and got a two-year warrant to purchase 387,739 shares at C$0.41 each, and a fee of 4.8% of gross proceeds (9/16)

Corautus
Genetics Inc.
(AMEX:CAQ)

Private placement of stock and warrants

0.943S and 0.236W

$4.93

Corautus closed the second tranche of a financing; the first tranche in July involved the same number of shares and warrants on the same terms; the 235,869 warrants are exercisable at a 20% premium at the time of the deal (9/23)

ChondroGene
Ltd.
(Canada; VSE:CDG)

Private placement of stock

0.526S

$0.5

PowerOne Capital Markets Ltd. placed the shares in Canada at $0.95 each; PowerOne got $30,000 and a warrant to purchase 31,578 shares at the same price (9/13)

DNAPrint
genomics Inc.
(OTC BB:DNAP)

Private
placement of
stock

N/A

$35

Dutchess Private Equities Fund committed to purchase $35M in DNAPrint stock over two years, at times and in amounts selected by DNAPrint; Athena Capital Partners arranged the deal (9/28)

Encysive
Pharmaceuticals
Inc.
(ENCY)

Private placement of stock

4.6S

$36.5

Encysive sold the shares that were covered under a shelf registration at $7.94 each to Wachovia Securities; the totals include 600,000 shares bought by Wachovia to cover overallotments (9/8)

Helix BioPharma
Corp.
(Canada; TSE:HBP)

Private placement of stock and warrants

0.225S and 0.225SW

C$0.62 (US$0.48)

Warrants issued in the private placement are exercisable at C$4.50 per share; other details on the financing were not disclosed (9/22)

Helix
BioPharma
Corp.
(Canada;
TSE:HBP)

Private
placement of
stock and
warrants

2.19S and
2.19W

C$4.66
(US$3.6)

The securities were sold to Canadian investors, including Sherfam Inc., the holding company for the Apotex Group of companies; the two and a half year warrants are exercisable at C$3 per share (9/1 and 9/16)

Human Genome
Sciences Inc.
(HGSI)

Private placement of convertible notes

N/A

$250

Institutional investors purchased the 2.25% convertible subordinated notes due 2011, which are convertible into common stock at $15.55 per share; they have an option to buy another $50M in notes (9/29)

INYX Inc.
(OTC BB:IYXI)

Private placement of stock and warrants

9.19S and 9.19W

$7.4

In one private placement, INYX raised $1.1M from the sale of stock and warrants to institutional investors affiliated with Sands Brothers Inter- national; in a $6.3M financing, INYX paid placement agent Sands Brothers a 10% fee; the five-year warrants carry exercise prices ranging from $1 to $1.11 per share (9/8)

Medical
Discoveries Inc.
(OTC BB: MLSC)

Private
placement of
stock

ND

$0.5

Private investors purchased the restricted stock under undisclosed terms (9/29)

Myogen Inc.
(MYOG)

Private placement of stock and warrants

9.2S and 1.8W

$60

The shares were sold at $6.525 each and the warrants are exercisable at $7.80 per share; investors included New Enterprise Associates, InterWest Partners, Perseus-Soros Biopharmaceutical Fund and Sequel Venture Partners; CIBC World Markets and Lazard Freres & Co. LLC were joint placement agents (9/27)

Nanobac Life
Sciences Inc.
(OTC BB:NNBP)

Private placement of stock

ND

$5

Nutmeg Group led the financing, which potentially will bring $5M to the company over the next four quarters (9/30)

NicOx SA (France; Nouveau Marche: NICOX)

Private placement of stock

9.44S

€26 (US$32.2)

The shares were sold at €2.75 each to 15 European and U.S. institutional investors (9/30)

Provalis plc
(UK; LSE:PRO)

Private
placement of
stock

33.07S

£2.6
(US$4.66)

The shares were placed mostly with institutional investors by Evolution Beeson Gregory at 8 pence per share, a discount of about 3% to the previous day's close (9/17)

Resverlogix
Corp.
(Canada;
VSE:RVX)

Private placement of stock

1.88S

C$0.4 (US$0.32)

The shares were sold to a small number of individuals at C$2.15 each; a 7% finder's fee was paid to a third party (9/23)

Sepracor Inc.
(SEPR)

Private placement of notes

N/A

$500

The 0% convertible senior subordinated notes due 2024 are convertible into cash plus, under certain circumstances, shares of Sepracor stock at $67.20 per share (9/17)

YM Biosciences Inc. (Canada; TSE:YM)

Bought-deal financing

4.3U

C$19.8 (US$15.33)

An underwriting group led by Dundee Securities Corp. and including Canaccord Capital Corp., Sprott Securities, Dlouhy Merchant Group and Haywood Securities bought the units at C$3.15 each; the units consist of one share and half a warrant; each whole warrant is exercisable for three years at C$3.75; the totals include the underwriters' purchase of 2M shares under their option (9/14)


Notes:

This chart does not include real estate or manufacturing plant financings.

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

@ Dates refer to the date of the press release.

Currency conversions are based on exchange rates at the time of the deal.

N/A = Not applicable; ND = Not disclosed.

AMEX = American Stock Exchange; ASX = Australian Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange.

No Comments